In preclinical studies, a combination of therapeutic agents that target the PI3K/AKT/mTOR signaling pathways has shown considerable anti-proliferative and pro-apoptotic activity against MCL cells. The gene discussed is AKT1; the disease is mantle cell lymphoma.